Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Summary

Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can 1. improve anemia (lead to an increased hemoglobin level) 2. reduce nosebleeds.

Timeline

Start

2002-03

Primary completion

2002-08

Completion

2002-10

Outcome

Missed primary endpoint

paper Hemoglobin levels, the primary outcome measure, did not change significantly (p=0.33). PMID 25005464 ↗

Publications

• Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014 Sep;134(3):565-71. doi: 10.1016/j.thromres.2014.06.012. Epub 2014 Jun 16.

Drugs

Indications